Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of
Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.
For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Davidi was the VP Product Management, Population Health in Allscripts where he managed the product life cycle from strategic planning and product roadmap to tactical activities, specifying and prioritizing market requirements for the Population Health products. Prior to Allscripts, he was the VP Professional Services for dbMotion Ltd., managed the company enterprise-wide projects in North America,
planning and implementation of dbMotion technologies at customer sites, developing product assimilation methodologies and providing the technical focal point for system integration, customer support and training. He has a BSc degree in Industrial Engineering and MBA degree from the Ben Gurion University in Israel

Josh has responsibility for the strategy, implementation, and growth of the US market for DayTwo.
Since joining the leadership team in 2017, Josh has developed the company’s US strategy, recruited and staffed the US team to support and serve consumers, providers, and employers.
Prior to DayTwo, Josh was CEO of Keas (acquired by Welltok), a health benefits solution for employers that catalyzed employee engagement to utilize healthcare benefits, CRO for YouSendIt (acquired by Western Digital), and Chief Strategy & Revenue Officer for TicketsNow (acquired by Ticketmaster). Prior to TicketsNow, Josh spent 10 years marketing to consumers online at AOL, as the General Manager of eCommerce.
Originally from Boston, Massachusetts, Josh has lived in New York, Illinois, and Virginia. He currently resides in California with his wife and three small children, coaches special Olympics and serves on the investment and audit committees as a Trustee of the Presbyterian Pension Fund.

Amir oversees DayTwo’s commercial activity in international markets.
Amir brings a wide range of leadership experience in building and managing commercial teams that drive rapid growth in international markets. Before Joining DayTwo, Amir served as Executive VP of Business Development at Signals Analytics, a technology-driven, Saas company that is funded by Sequoia Capital, where he played a key role penetrating US and European
markets, dramatically expanding the global customer base to over 50 Fortune 1000 companies.
Before joining Signals, Amir was a Co-Founder and Managing Partner at Arazim Agro, an Israeli agritech company. He served as an Intelligence Officer in the Israeli Air Force and as Assistant to the Israeli Defense Attache in Washington DC. Amir holds an MBA from Ben Gurion University.

Noa has 15 years of experience in product management, specializing in data and mobile products, B2C and B2B2C. Prior to DayTwo, she worked as a Product Manager at Copilot.cx, a Startup enabling Consumer Electronics companies to rely on smart segmentation to improve the customer journey and lifetime value for users.

In her previous roles, she managed the product group and user experience characterization at Zamingo, which provides product strategy consulting, user research and user experience characterization for leading companies in the US and Israeli markets. Additionally, she managed leading mobile products as part of Orange’s innovation unit and took part in the creation of novel products in the US market as part of a startup in 2004.

Aaron has spent 15+ years in the life science tools and technologies sector developing medical devices and services to democratize access to omics information at scale. Most recently, he was VP Technology at DNA Genotek (acquired by OraSure) and launched their Microbiome Program in 2014.

Aaron led that division through 5 years of triple digit growth and expanded it through M&A (CoreBiome, Diversigen) to include lab and computational services. Aaron has a degree in molecular biology from McMaster, studied Autism Genetics at Queen’s and has had the privilege to help grow companies recognized as Technology Pioneers by the World Economic Forum.

Adi brings 20 years of experience in the worlds of Software Development and expertise in the domain of Data Analytics, from enterprise (Intel) and leading mid size companies (Optimal plus, Cellebrite) to top innovative startups (RapidAPI).

As an executive VP and R&D director during the last 10 years, Adi holds a proven record of designing software architecture for complex cloud based and SAAS solutions, as well as with building and managing large, highly effective and fast growing R&D teams, while utilizing best in class engineering flows and practices. Adi holds a BSc in Information Systems Engineering from Ben Gurion University.

Tal has many years of professional experience in Project Management in a variety of fields, Business Development and Regulation. In her position at DayTwo, Tal is responsible for managing and leading projects at the core of the company’s operations. Prior to joining DayTwo, she worked in a variety of positions, both in the public and private sectors. She led and managed projects in the field of renewable energy within the FK Group international business operations, served in key regulatory and licensing roles in the Ministry of Communications and provided research and consulting services to government offices and various business entities.

In 2005, Tal was selected as the Israeli Fellow for the Eisenhower Fellowships Multinational Program. She holds a Ph.D in law from Oxford University, England.

Eran is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Syste ms biology. His research focuses on studying the relationship between nutrition, health and gut microbes in human individuals.
Prof. Segal published over 110 publications, and received several awards and honors for his work, including the EMBO young investigator award, the Michael Bruno award, and the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in the field of computational biology. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.
Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a PhD. in Computer Science and Genetics in 2004, from Stanford University.

Eran is a Professor leading a research group at the Immunology Department of the Weizmann Institute of Science. His group focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition.
Prof. Elinav published over 110 publications, and received several awards for his work, including the 2013 Alon prize, and the 2015 Rappaport prize, awarded annually to one scientist for outstanding accomplishments in the field of biomedical research.
Before joining the Weizmann Institute, Prof. Elinav held an independent research position as a physician-Scientist at the Institute for Gastroenterology and Liver disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.

Dariush Mozaffarian is a cardiologist and epidemiologist; Co-Director of the Program in Cardiovascular Epidemiology; Associate Professor in the Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School; and Associate Professor in the Department of Epidemiology at the Harvard School of Public Health. His research focuses on the effects of lifestyle, particularly diet, on cardiometabolic health and disease; on global impacts of suboptimal nutrition on chronic diseases; and on effectiveness of policies to improve diet and reduce disease risk.

Dr. Mozaffarian has authored or co-authored more than 200 scientific publications on lifestyle and cardiovascular health, including on global dietary burdens of disease, omega-3 fatty acids, trans fatty acids, diets and weight gain, and healthy dietary patterns. He has served on numerous committees and advisory boards, including for the World Health Organization, United Nations Food and Agriculture Organization, American Heart Association, Canadian government, and Chicago Council on Global Affairs. He chairs the 2010 Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE).

A Fellow of the American College of Cardiology and a Fellow of the American Heart Association, Dr. Mozaffarian received a BS in biological sciences from Stanford (with Honors, Phi Beta Kappa), an MD from Columbia (Alpha Omega Alpha), an MPH from University of Washington, and a Doctorate in Epidemiology from Harvard. He is board-certified in Cardiovascular Medicine and is clinically active on the cardiology service at Brigham and Women’s Hospital.

Dr. Krauss is Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, Adjunct Professor of Medicine at UCSF, and Adjunct Professor of Nutritional Sciences at UC Berkeley. He received his undergraduate and medical degrees from Harvard University with honors and served his internship and residency on the Harvard Medical Service of Boston City Hospital. He then joined the staff of the National Heart, Lung, and Blood Institute in Bethesda, Maryland, first as Clinical Associate and then as Senior Investigator in the Molecular Disease Branch.

Dr. Krauss is board-certified in internal medicine, endocrinology and metabolism, and is a member of the American Society for Clinical Investigation, a Fellow of the American Society of Nutrition and the American Heart Association (AHA), and a Distinguished Fellow of the International Atherosclerosis Society. He has served on the U.S. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, was the founding chair of the AHA Council on Nutrition, Physical Activity, and Metabolism, and is a National Spokesperson for the AHA.

Dr. Krauss has also served on both the Committee on Dietary Recommended Intakes for Macronutrients and the Committee on Biomarkers of Chronic Disease of the Institute of Medicine of the National Academy of Sciences. He has received numerous awards including the AHA Scientific Councils Distinguished Achievement Award, the Centrum Center For Nutrition Science Award of the American Society for Nutrition, the Distinguished Leader in Insulin Resistance from the International Committee for Insulin Resistance, and the AHA Award of Meritorious Achievement. In addition he has been the Robert I. Levy Lecturer of the AHA, the Edwin Bierman Lecturer for the American Diabetes Association, and the Margaret Albrink Lecturer at West Virginia University School of Medicine.

Dr. Krauss is on the editorial boards of a number of journals, and has been Associate Editor of Obesity, the Journal of Lipid Research, and the Journal of Clinical Lipidology. He has published over 400 research articles and reviews on genetic, dietary, and drug effects on plasma lipoproteins and coronary artery disease. Among his accomplishments is the identification of atherogenic dyslipidemia, a prevalent lipoprotein trait (high triglyceride, low HDL, and increase in small, dense LDL particles) that is associated with risk of cardiovascular disease and type 2 diabetes.

In recent years Dr. Krauss’ work has focused on interactions of genes with dietary and drug treatments that affect metabolic phenotypes and cardiovascular disease risk.

Rob Knight is the founding Director of the Center for Microbiome Innovation and Professor of Pediatrics and Computer Science & Engineering at UC San Diego. Before that, he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. He is a Fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. He received the 2017 Massry Prize for his microbiome research. In 2015 he received the Vilceck Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015), coauthor of “Dirt is Good: The Advantage of Germs for Your Child’s Developing Immune System (St. Martin’s Press, 2017) and spoke at TED in 2014. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 10,000 times as of this writing) and UniFrac (cited over 5000 times including its web interface). He is co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc., which uses DNA from microbes in the subsurface to guide oilfield decisions. His work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and made high-throughput sequencing techniques accessible to thousands of researchers around the world. Dr. Knight can be followed on Twitter (@knightlabnews) or on his web site http://knightlab.ucsd.edu/.

Dr. Jack A. Gilbert earned his Ph.D. from Nottingham University, UK, in 2002 and received his postdoctoral training in Canada at Queens University. Subsequently, he returned to the UK in 2005 to work for Plymouth Marine Laboratory as a senior scientist until his move to Argonne National Laboratory and the University of Chicago in 2010. Professor Gilbert was the Director of the Microbiome Center and a Professor of Surgery at the University of Chicago. Currently, Dr. Gilbert is a Professor in the Department of Pediatrics and the Scripps Institution of Oceanography at University of California, San Diego. He is also Group Leader for Microbial Ecology at Argonne National Laboratory, Research Associate at the Field Museum of Natural History, Scientific Fellow at the Marine Biological Laboratory, and the Yeoh Ghim Seng Visiting Professorship in Surgery at the National University of Singapore. Dr. Gilbert uses molecular analysis to test fundamental hypotheses in microbial ecology. He has authored more than 250 peer reviewed publications and book chapters on metagenomics and approaches to ecosystem ecology. He is the founding Editor in Chief of mSystems journal. In 2014, he was recognized on Crain’s Business Chicago’s 40 Under 40 List, and in 2015, he was listed as one of the 50 most influential scientists by Business Insider, and in the Brilliant Ten by Popular Scientist. In 2016, he won the Altemeier Prize from the Surgical Infection Society, and the WH Pierce Prize from the Society for Applied Microbiology for research excellence. He also co-authored “Dirt is Good” published in 2017, a popular science guide to the microbiome and children’s health. He serves on the board of the Genomic Standards Consortium and is the primary investigator for various research ventures, including the Earth Microbiome Project, the Home Microbiome Project, the Gulf Microbial Modeling Project, the Hospital Microbiome Project, and the Chicago River Microbiome Project.

Alan is an Advisor for Clinical Affairs at DayTwo. He is currently SVP for Strategy and Analytics and Chief Medical Officer for Blue Health Intelligence. He has over 30 years of clinical, health strategy, healthcare IT, clinical informatics and change management experience and is considered a leading innovator in health care management.

Dr. Spiro has a varied background including having been Chief Medical Officer at Medica, a health services company, and a co-founder of Accolade, Inc., an on-demand healthcare concierge for employers, health plans, and health systems that he grew from 7 employees to 700. At Accolade, Alan served as Senior Vice President and Chief Medical Officer where he spearheaded the development of health advocacy programs that significantly improved health outcomes, resulting in substantial cost savings and clinical quality improvement. Alan served as Vice President, Chief Medical Officer National Accounts at Anthem, Inc. and prior to that was a Partner and leader of the Clinician Section of the Health Management Practice at Towers Perrin (now Willis Towers Watson) serving the Fortune 500 employers. He was a founder of AIM, now owned by Anthem.

Alan holds an MD degree from the Columbia University College of Physicians and Surgeons, an MBA degree from the Kellogg School of Management at Northwestern University, and a BA degree from New York University. Additionally, he completed a joint MIT Harvard Research Fellowship in Nutrition at New England Deaconess Hospital in Boston and a Harvard Clinical Fellowship in Gastroenterology at Beth Israel Hospital in Boston, as well as a University of Chicago Affiliated Residency in Internal Medicine.

Alan is a frequent speaker at national healthcare conferences, and he is currently on the Board of Directors for the Institute for Practice and Provider Performance Improvement. He has consulted at many major universities, and Fortune 100 companies as well as for the VA system. Additionally, Alan has been a visiting professor for the Michigan State University Sloan School of Business, the University of Georgia College of Public Health, and the Harvard School of Public Health as well as other universities.

Jan is a tri-sector healthcare executive that has proven results as a senior executive in the three sectors of private, public and government services over the last 30 years. In 2009 Jan founded Health Intelligence Partners as a health care consultancy that blends more than thirty years of business and clinical experience. Health Intelligence Partners has a global focus (engagements in 14 countries with both Health Organizations and National Ministries of Health), working with clients on areas of growth including short-term and long-term business strategies and solutions. Health Intelligence Partners helps clients to navigate intersection of strategy and operations within both the healthcare and consumer goods and services environment in order to identify and articulate value opportunities.

Prior to founding Health Intelligence Partners, Jan served as Senior Vice President, Chief Clinical Officer and Innovation Officer for CVS Health/Caremark. During that time, she was a corporate officer and on the executive team with P & L (500 million-dollar business unit), operations and strategic experience. Jan also lead Caremark’s Medicare Part D development and was the clinical lead for CVS Caremark’s M & A activity. During this time, Jan developed an expertise in both healthcare and retail consumer behavior. Before going to CVS Caremark, Jan had 15 years’ experience in healthcare administration within the health plan and academic arenas and lead operations for two population health companies.

As a veteran healthcare executive, Jan’s leadership has delivered results in a variety of settings. Jan offers her experiences and insights through her consulting agency as well as through her participation on healthcare and consumer product boards. She presently sits on healthcare focused boards including), GNS Healthcare (Vice Chair of the Board, Chair; Governance/Compensation/Nomination Committee, M&A/Strategy Committee), Cambia Health Solutions (Consumer Engagement Platform Committee, Health Services Committee), Tabula Rasa (Nominations, Compensation, Governance), UCB Pharmaceuticals and Voluntis Health Care (Chair, M&A/Strategy Committee). Jan’s consumer focused boards have included Savor Health, Care Heroes and Whiskerdocs. Jan previous board experience includes; Care Core National (Committees: Audit and Finance Committee, Compensation, Search, M&A and Strategic Directions), AccentCare (Chair; Compliance Committee, Compensation Committee), Qliance and Rx-Ante. She also sits on numerous business and healthcare advisory boards.

As the author of the books “Leveraging Health”, “Thirteen Common Pitfalls in Consumer Engagement”, “We Don’t Talk Anymore: A Consumer’s Guide to Connecting with their Doctor” and “Medical Liability for Pediatricians”, the past Editor in Chief of American Journal of Pharmacy Benefit and on the editorial boards of a number of healthcare journals, Jan is considered a national health care thought leader. Jan speaks and writes on a broad range of health care and pharmaceutical services issues.

Jan holds both a Doctor of Medicine degree and a master’s degree in jurisprudence from Loyola University in Chicago, and a Certificate in Healthcare Business Administration from University of South Florida. She also holds a black belt in Six Sigma. Jan is an assistant professor at Northwestern University School of Medicine and School of Communication in Chicago, Illinois where she teaches the Engaging the Consumer in Health course.

Melinda Maryniuk is an award winning diabetes educator with over 35 years of experience bringing innovative education resources to patients, healthcare professionals and organizations.

As Director of Care Programs for Joslin Diabetes Center, she worked to improve diabetes education services with leading diabetes centers around the country. She has developed and delivered training programs for physicians, diabetes educators, medical office assistants, employees in diabetes business units, as well as people affected by diabetes.

Melinda has worked on diabetes education projects around the world including China, India, Japan, Kuwait, Saudi Arabia and Brazil. Through Melinda’s extensive global and national experience, she draws from a wide network of experts to ensure diverse needs and deadlines can be met.

Currently, Melinda is the Lead Diabetes Educator for Diabetes- What to Know and for My Weight – What to Know, an educational resource and Facebook community for people with type 2 diabetes and for those managing overweight or obesity.